Although right ventricular failure (RVF) is the hallmark of
pulmonary arterial hypertension (PAH), the mechanism of RVF is unclear. Development of PAH-induced RVF is associated with an increased
reactive oxygen species (ROS) production. Increases in oxidative stress lead to generation of nitro-
tyrosine residues in
tissue inhibitor of metalloproteinase (TIMPs) and liberate active
matrix metalloproteinase (
MMPs). To test the hypothesis that an imbalance in
MMP-to-TIMP ratio leads to interstitial
fibrosis and RVF and whether the treatment with
folic acid (FA) alleviates ROS generation, maintains
MMP/TIMP balance, and regresses interstitial
fibrosis, we used a mouse model of pulmonary artery constriction (PAC). After surgery mice were given FA in their
drinking water (0.03 g/l) for 4 wk. Production of ROS in the right ventricle (RV) was measured using oxidative
fluorescent dye. The level of MMP-2, -9, and -13 and TIMP-4, autophagy marker (p62), mitophagy marker (LC3A/B),
collagen interstitial
fibrosis, and ROS in the RV wall was measured. RV function was measured by Millar
catheter. Treatment with FA decreased the pressure to 35 mmHg from 50 mmHg in PAC mice. Similarly, RV volume in PAC mice was increased compared with the
Sham group. A robust increase of ROS was observed in RV of PAC mice, which was decreased by treatment with FA. The
protein level of MMP-2, -9, and -13 was increased in RV of PAC mice in comparison with that in the
sham-operated mice, whereas supplementation with FA abolished this effect and mitigated
MMPs levels. The
protein level of TIMP-4 was decreased in RV of PAC mice compared with the
Sham group. Treatment with FA helped PAC mice to improve the level of TIMP-4. To further support the claim of mitophagy occurrence during RVF, the levels of LC3A/B and p62 were measured by Western blot and immunohistochemistry. LC3A/B was increased in RV of PAC mice. Similarly, increased p62
protein level was observed in RV of PAC mice. Treatment with FA abolished this effect in PAC mice. These results suggest that FA treatment improves
MMP/TIMP balance and ameliorates
mitochondrial dysfunction that results in protection of RV failure during
pulmonary hypertension.